NCT06429098View on ClinicalTrials.gov

Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

June 30, 2027

Study Completion Date

December 31, 2027

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Venetoclax

Given PO, once daily. Treatment in cycle 1, the dose is 100 mg on day 1, then ramp up to 400mg. In all subsequent cycles, the dose of venetoclax is initiated at 400 mg daily.

DRUG

azacitidine

Given SC

DRUG

decitabine

Given IV

DRUG

Cytarabine

Given IV

Trial Locations (2)

215000

RECRUITING

Ethical Committee of the First Affiliated Hospital of Soochow University, Suzhou

RECRUITING

The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou

All Listed Sponsors
lead

The First Affiliated Hospital of Soochow University

OTHER